- Home
- TTNP vs APM Comparison
TTNP vs APM Comparison
Compare TTNP & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTNP
- APM
- Stock Information
- Founded
- TTNP 1991
- APM 2010
- Country
- TTNP United States
- APM United Kingdom
- Employees
- TTNP N/A
- APM N/A
- Industry
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- TTNP Health Care
- APM Health Care
- Exchange
- TTNP Nasdaq
- APM Nasdaq
- Market Cap
- TTNP 5.4M
- APM 6.9M
- IPO Year
- TTNP 1996
- APM 2018
- Fundamental
- Price
- TTNP $4.38
- APM $1.61
- Analyst Decision
- TTNP
- APM
- Analyst Count
- TTNP 0
- APM 0
- Target Price
- TTNP N/A
- APM N/A
- AVG Volume (30 Days)
- TTNP 17.4K
- APM 10.2M
- Earning Date
- TTNP 08-14-2025
- APM 08-05-2025
- Dividend Yield
- TTNP N/A
- APM N/A
- EPS Growth
- TTNP N/A
- APM N/A
- EPS
- TTNP N/A
- APM N/A
- Revenue
- TTNP N/A
- APM N/A
- Revenue This Year
- TTNP N/A
- APM N/A
- Revenue Next Year
- TTNP N/A
- APM N/A
- P/E Ratio
- TTNP N/A
- APM N/A
- Revenue Growth
- TTNP N/A
- APM N/A
- 52 Week Low
- TTNP $3.03
- APM $0.46
- 52 Week High
- TTNP $14.80
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- TTNP 47.75
- APM 57.33
- Support Level
- TTNP $3.82
- APM $1.40
- Resistance Level
- TTNP $5.35
- APM $1.97
- Average True Range (ATR)
- TTNP 0.42
- APM 0.42
- MACD
- TTNP -0.01
- APM 0.04
- Stochastic Oscillator
- TTNP 36.60
- APM 21.00
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.